In January 2026 Merck and Moderna reported median five-year follow-up data from their Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of intismeran autogene plus Keytruda in high-risk stage III/IV melanoma patients. The combination therapy maintained a 49% reduction in risk of recurrence or death compared with Keytruda alone—identical to the three-year result announced in 2023—underscoring sustained immune protection. Safety remained consistent with prior analyses, and the companies plan to present full primary and secondary endpoint data at an upcoming oncology congress. With roughly 112,000 new U.S. melanoma cases expected in 2026 and potential pricing aligned with established immunotherapies, analysts forecast multi-billion-dollar peak sales in melanoma, bolstering Merck’s strategy to expand its oncology franchise beyond checkpoint inhibitors.

In early 2026 Merck inked a multi-year agreement with Guardant Health to leverage the Guardant Infinity Smart platform for Merck’s development and commercialization of its oncology pipeline. The partnership will integrate circulating tumor DNA assays into Merck’s clinical programs, enabling non-invasive genomic profiling to identify resistance mutations and guide patient selection across multiple solid tumors. With over 300 million lives covered by the platform’s reimbursement footprint, this collaboration is expected to accelerate Merck’s late-stage trial enrollment, reduce biopsy-related delays, and support real-time monitoring of minimal residual disease, thereby enhancing trial efficiency and potentially improving response rates to Merck’s targeted and immuno-oncology agents.

In September 2025 Merck entered into a strategic alliance with Biocytogen Pharmaceuticals to co-develop antibody-conjugated lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. The collaboration focuses on engineering LNPs anchored with tumor-targeting antibodies to improve payload specificity and cellular uptake in solid tumors. By combining Merck’s oncology discovery capabilities with Biocytogen’s proprietary LNP manufacturing platform, the partners aim to advance precision mRNA and siRNA therapies into preclinical development within 12 to 18 months. Success in this program could establish a new class of targeted delivery vehicles to enhance the therapeutic index of Merck’s future nucleic acid-based cancer vaccines and gene-silencing candidates.